Xiaozhong Jiedu Powder Veterinary Grade API is supplied as a non-sterile multi-component botanical powder intended for further processing into tablets, injections, capsules, powders, granules, premixes, and solutions under veterinary GMP. The product is not assigned a discrete model number; batch traceability is maintained through the manufacturer’s lot code, the date of manufacture, and the certificate of analysis. Because the material is a botanical multi-constituent API rather than an isolated single chemical entity, its specification combines general pharmacopoeial release tests with any marker-based identity method recorded in the marketing authorization dossier. Published data for this specific branded configuration is limited, and users of the API should treat the registered specification as the controlling document rather than relying on generic botanical powder values.

Incoming inventory is in the non-sterile state and requires quarantine release before dispensing. The material is used as a starting substance in the manufacture of finished veterinary medicinal products; it is not presented as a sterile or ready-to-use preparation. For tablet and capsule manufacturing, the powder is typically dry-blended or granulated; for solutions and injectable preparations, dissolution or dispersion is followed by clarification and, where required, sterilising-grade filtration. Because the botanical matrix may contain fibre, saponins, and polyphenolic species, processability varies across milling campaigns and harvest seasons. Incoming lots are therefore tested against the marketing authorization holder’s registered limits for loss on drying, total ash, particle size distribution, and microbial enumeration before use.

What Release Specifications and Compendial Methods Are Used to Control Multi-Constituent Veterinary Powders?

Release evaluation for a botanical veterinary API of this type is performed against a specification that typically includes appearance, identity, loss on drying, total ash, elemental impurities or heavy metals, microbial enumeration, and particle size distribution. Compendial test methods from USP <731>, Ph. Eur. 2.2.32, USP <281>, Ph. Eur. 2.4.16, and ISO 13320:2020 provide the measurement basis where a product-specific monograph does not exist. Identity testing for a multi-constituent powder may rely on thin-layer chromatography or high-performance liquid chromatography marker fingerprints rather than a single infrared spectrum. The acceptance criteria for marker content are product-specific and are not published as universal values. Instead, the manufacturer’s certificate of analysis reports the assigned marker compound or the total extractive content, depending on the registered method.

For powders intended only for solid oral forms, the microbial enumeration limits of USP <61> and USP <62> are common acceptance gateways. For injectable production, the non-sterile API must also be evaluated for bacterial endotoxins using USP <85> or Ph. Eur. 2.6.14, because the pyrogen load is not automatically removed by sterile filtration. The elemental impurity platform is aligned with ICH Q3D and USP <232>/USP <233>; botanical raw materials can accumulate lead, cadmium, arsenic, and mercury from soil, and therefore batch-to-batch monitoring is required for injectable or long-duration oral applications.

These methods are baseline release tools; a product-specific veterinary monograph, if registered, may impose additional tests for residual solvents, pesticide residues, or aflatoxins. The absence of a public monograph for Xiaozhong Jiedu Powder means that the exact numerical release limits are confidential to the marketing authorization, and published compendial general chapter values must not be used as product acceptance limits.

During tablet production at commercial scale, the untreated powder is rarely suitable for direct compression on a rotary press. A 16-station press operated at 8 kN to 18 kN main compression force and 2.0 kN to 3.5 kN pre-compression force may show weight variation above 2% if the powder’s angle of repose exceeds 40° and the feed frame speed is not matched to the granule size. The botanical matrix’s broad particle size distribution segregates during transfer and die filling; fines migrate to the bottom of the hopper while coarse fibrous particles accumulate near the top. Consequently, wet granulation in a high-shear mixer with impeller tip speed of 5 m/s to 10 m/s and binder solution added by peristaltic pump is the most frequently evaluated route to improve content uniformity. Endpoint is controlled by impeller power draw and product temperature, not by fixed granulation time, because the fibre fraction can absorb binder solution unevenly across batches.

Roller compaction offers a dry granulation alternative when aqueous granulation may hydrolyse susceptible constituents. Roll pressure is typically set between 6 MPa and 12 MPa, with roll gap of 1.0 mm to 2.0 mm and roll speed of 5 rpm to 15 rpm. The resulting ribbons are milled through a cone mill fitted with a screen aperture of 0.5 mm to 1.0 mm. The compaction step can reduce segregation, but if the botanical powder contains high fibre content, the ribbons may be brittle and produce excessive fines. In such cases, a dry binder such as microcrystalline cellulose is included before compaction to improve ribbon tensile strength.

Capsule filling on a tamping-pin machine is adjusted to achieve fill weight coefficient of variation below 3% for the granulation. Powder and granule sachets are filled by volumetric auger or weigh-cell equipment; blend uniformity is accepted only when 10 or more stratified samples fall within 90% to 110% of the marker compound claim. Premix preparation for veterinary feed applications uses geometric dilution into a carrier such as lactose monohydrate, dextrose, or wheat middlings; the final premix is tested for marker uniformity with a relative standard deviation below 5%. In a twin-screw wet granulator with length-to-diameter ratio of 25:1 to 40:1, the powder can be continuously granulated at throughputs between 10 kg/h and 60 kg/h depending on the available equipment; however, published data for this specific product configuration is limited.

Non-injectable solutions are usually compounded as oral liquids, with the API dispersed or dissolved in purified water containing preservatives such as sodium benzoate at 0.1% to 0.2% w/v. The liquid is passed through a 5 µm or 1 µm clarifying filter before filling; if visible botanical particles remain, the product is reformulated as a suspension with hydroxyethylcellulose or xanthan gum to control sedimentation. pH is adjusted with citric acid or sodium hydroxide after considering marker stability. Density and viscosity of the finished solution are measured at 20 °C to 25 °C to ensure consistent fill volumes.

When Terminal Sterilisation Is Not Feasible for Injectable Compounding

When terminal sterilisation is not feasible for injectable compounding, the manufacturing route shifts to aseptic filtration of a solution or submicron dispersion. The non-sterile botanical API must first be dissolved or dispersed in a validated solvent system; the resulting liquid is clarified through depth filtration and then passed through a 0.22 µm sterilising-grade membrane. A 0.45 µm prefilter is placed upstream to reduce particulate load and extend membrane life. Multi-component botanical streams with polyphenolic or saponin content can foul the 0.22 µm membrane, producing flux decline greater than 50% within 10 minutes to 30 minutes of filtration at pilot scale. Filter compatibility trials are therefore performed at constant pressure not exceeding the membrane manufacturer’s stated maximum of 2.0 bar to 3.5 bar. The filtered solution is filled into pre-sterilised containers and closed under Grade A air supply. Sterility of the finished injectable preparation is confirmed by USP <71> or Ph. Eur. 2.6.1; bacterial endotoxins are controlled to the limit stated in the finished product dossier using USP <85>.

Terminal moist-heat sterilisation at 121 °C for 15 minutes is generally not assumed to be compatible with the botanical matrix unless thermal stability data are provided in the registration. Phytochemical markers may degrade or particulate agglomerates may form during heating. If the product is formulated as a suspension, the particle size distribution after steam sterilisation may shift outside the specification, and sedimentation can become irreversible. Because the API is supplied non-sterile, the release of a sterile injectable preparation requires the manufacturer to maintain a fully validated sterilising filtration or aseptic processing line; the API alone does not provide sterility assurance.

Differences From Synthetic Single-Entity Veterinary APIs in Solid Dosage Processing

Compared with a crystalline synthetic veterinary API, Xiaozhong Jiedu Powder presents several formulation differences. A synthetic single-entity API is usually controlled by a single assay method and can be blended according to one active content value; the botanical multi-constituent powder may require one or more marker compounds and a broader identity profile to establish batch-to-batch consistency. Content uniformity testing of finished tablets or capsules may therefore be reported against the assigned marker rather than a single chemical entity, and acceptance limits are derived from the registration dossier rather than from routine USP <905> uniformity of dosage units criteria alone.

Physically, the powder exhibits lower bulk density and higher water activity than a typical crystalline API. The powder may require milling to reduce fibrous particles before capsule filling or tableting. The presence of hygroscopic carbohydrate or saponin fractions can cause moisture uptake at relative humidity above 60%; by contrast, many synthetic small-molecule APIs remain free-flowing under the same ambient conditions. This difference in hygroscopicity means that the botanical powder is handled in air-conditioned suites and pre-dried before direct compression if loss on drying exceeds the registered limit.

Another distinction is microbiological burden. A synthetic API can be accepted with relatively low bioburden due to the solvent-based crystallisation and drying steps; a botanical powder of natural origin may have a higher native microbial load and requires a stricter incoming microbial enumeration threshold. Consequently, blending and granulation equipment for the botanical API is cleaned and dried with more frequent monitoring for residual moisture and microbial contaminants. The cleaning validation matrix must address the removal of fibre, polyphenolic residues, and microbial soils, which may not be relevant to a synthetic single-entity API.

Because the material is organic botanical dust, storage and handling operations are subject to combustible dust precautions aligned with NFPA 654. The powder should be kept in sealed polyethylene-lined fibre drums or equivalent containers, in a controlled environment below 25 °C and 60% relative humidity. Pre-drying is required when moisture content exceeds the registered limit; drying in a tray oven or fluid-bed dryer must not exceed the temperature stated in the batch record, because botanical marker degradation may occur above 60 °C to 70 °C depending on the constituent profile. The material is incompatible with strong oxidising agents in dry blending and should not be exposed to open flame or ignition sources during milling or sieving. For injectable manufacturing, the non-sterile powder must be stored separately from sterilised components, and any transfer into the aseptic core occurs through a pre-sterilised pass-through after surface decontamination.

Cleaning and carryover control require validated analytical methods for the marker compound. Shared lines with synthetic veterinary APIs must be cleaned with a detergent system capable of removing polyphenolic residues and fibrous particulates. If the product is used in food-producing species, the withdrawal period and maximum residue limit are defined by the finished product registration, not by the API powder itself. Published data for this specific configuration is limited, so process parameters must be confirmed on the intended production line. The registered specification, certificate of analysis, and site validation batches remain the governing documents for use of the material.